S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58
S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58
S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58
S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58

Agenus (AGEN) Stock Forecast, Price & News

+0.01 (+0.65%)
(As of 05/19/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
3.80 million shs
Average Volume
4.72 million shs
Market Capitalization
$417.32 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive AGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter.

Agenus logo

About Agenus

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$295.67 million
Book Value
$0.10 per share


Net Income
$-23.93 million
Pretax Margin




Free Float
Market Cap
$417.32 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.09 out of 5 stars

Medical Sector

487th out of 1,418 stocks

Biological Products, Except Diagnostic Industry

79th out of 210 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Agenus (NASDAQ:AGEN) Frequently Asked Questions

Is Agenus a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Agenus stock.
View analyst ratings for Agenus
or view top-rated stocks.

When is Agenus' next earnings date?

Agenus is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Agenus

How were Agenus' earnings last quarter?

Agenus Inc. (NASDAQ:AGEN) announced its quarterly earnings results on Tuesday, May, 10th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.11. During the same period last year, the firm posted ($0.27) earnings per share.
View Agenus' earnings history

What price target have analysts set for AGEN?

2 brokerages have issued 1-year target prices for Agenus' shares. Their forecasts range from $8.00 to $14.00. On average, they expect Agenus' stock price to reach $11.00 in the next year. This suggests a possible upside of 614.3% from the stock's current price.
View analysts' price targets for Agenus
or view top-rated stocks among Wall Street analysts.

Who are Agenus' key executives?
Agenus' management team includes the following people:
  • Dr. Garo H. Armen Ph.D., Founder, Exec. Chairman & CEO (Age 69, Pay $1.07M)
  • Ms. Christine M. Klaskin, VP of Fin., Principal Financial Officer & Principal Accounting Officer (Age 56, Pay $362.97k) (LinkedIn Profile)
  • Dr. Jennifer S. Buell Ph.D., Pres & CEO of MiNK Therapeutics (Age 46, Pay $707.92k)
  • Craig Winter, Chief Information Officer
  • Regina Grebla Ph.D., VP of Investor Relations & Communications
  • Ms. Tracy Mazza Clemente, Chief People Officer
  • John Castle, Head of Translational Medicine & Bioinformatics
  • Ms. Julie DeSander, Chief Bus. Officer
  • Mr. Paulo Moreira, Global Head of Clinical Operations
  • Mr. Dhan Chand, Scientific Director & Head of Drug Discovery
What is Garo H. Armen's approval rating as Agenus' CEO?

2 employees have rated Agenus CEO Garo H. Armen on Glassdoor.com. Garo H. Armen has an approval rating of 56% among Agenus' employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agenus own?
What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

Who are Agenus' major shareholders?

Agenus' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.81%), BlackRock Inc. (6.64%), State Street Corp (6.57%), Deep Track Capital LP (5.18%), Artal Group S.A. (2.03%) and Renaissance Technologies LLC (1.82%). Company insiders that own Agenus stock include Agenus Inc, Christine M Klaskin, Corp Incyte, Garo H Armen and Steven J O'day.
View institutional ownership trends for Agenus

Which institutional investors are selling Agenus stock?

AGEN stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, RTW Investments LP, Goldman Sachs Group Inc., Citigroup Inc., Artal Group S.A., UBS Group AG, Federated Hermes Inc., and Jane Street Group LLC. Company insiders that have sold Agenus company stock in the last year include Christine M Klaskin, Garo H Armen, and Steven J O'day.
View insider buying and selling activity for Agenus
or view top insider-selling stocks.

Which institutional investors are buying Agenus stock?

AGEN stock was bought by a variety of institutional investors in the last quarter, including Deep Track Capital LP, Renaissance Technologies LLC, Vanguard Group Inc., Pinz Capital Management LP, Morgan Jess S & Co. Inc., Panagora Asset Management Inc., Qube Research & Technologies Ltd, and BlackRock Inc..
View insider buying and selling activity for Agenus
or or view top insider-buying stocks.

How do I buy shares of Agenus?

Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agenus' stock price today?

One share of AGEN stock can currently be purchased for approximately $1.54.

How much money does Agenus make?

Agenus has a market capitalization of $417.32 million and generates $295.67 million in revenue each year. The biotechnology company earns $-23.93 million in net income (profit) each year or ($0.10) on an earnings per share basis.

How many employees does Agenus have?

Agenus employs 441 workers across the globe.

What is Agenus' official website?

The official website for Agenus is agenusbio.com.

How can I contact Agenus?

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at (781) 674-4400, via email at [email protected], or via fax at 781-674-4200.

This page was last updated on 5/20/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.